ATE463559T1 - Zelllinie zur produktion von coronaviren - Google Patents

Zelllinie zur produktion von coronaviren

Info

Publication number
ATE463559T1
ATE463559T1 AT06792538T AT06792538T ATE463559T1 AT E463559 T1 ATE463559 T1 AT E463559T1 AT 06792538 T AT06792538 T AT 06792538T AT 06792538 T AT06792538 T AT 06792538T AT E463559 T1 ATE463559 T1 AT E463559T1
Authority
AT
Austria
Prior art keywords
coronaviruses
production
cell line
relates
cov
Prior art date
Application number
AT06792538T
Other languages
English (en)
Inventor
Den Brink Edward Norbert Van
Meulen Jan Ter
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE463559T1 publication Critical patent/ATE463559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C12N2770/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06792538T 2005-07-22 2006-07-21 Zelllinie zur produktion von coronaviren ATE463559T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70202905P 2005-07-22 2005-07-22
EP05106768 2005-07-22
PCT/EP2006/064489 WO2007010028A1 (en) 2005-07-22 2006-07-21 Cell line for producing coronaviruses

Publications (1)

Publication Number Publication Date
ATE463559T1 true ATE463559T1 (de) 2010-04-15

Family

ID=35445861

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06792538T ATE463559T1 (de) 2005-07-22 2006-07-21 Zelllinie zur produktion von coronaviren

Country Status (10)

Country Link
US (1) US7888102B2 (de)
EP (1) EP1907536B1 (de)
JP (1) JP5137829B2 (de)
KR (1) KR101274790B1 (de)
CN (1) CN101228267B (de)
AT (1) ATE463559T1 (de)
AU (1) AU2006271666B2 (de)
CA (1) CA2616221C (de)
DK (1) DK1907536T3 (de)
WO (1) WO2007010028A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
ATE463559T1 (de) 2005-07-22 2010-04-15 Crucell Holland Bv Zelllinie zur produktion von coronaviren
HRP20130163T1 (hr) 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
CN111273016B (zh) * 2020-02-26 2021-06-15 浙江诺迦生物科技有限公司 一种基于s蛋白配体与ace2受体竞争法层析的冠状病毒快速检测的试剂盒
WO2021207303A1 (en) * 2020-04-07 2021-10-14 Alsatech, Inc. Immune stimulation against coronavirus infections
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2021214467A1 (en) * 2020-04-23 2021-10-28 Cellbio A diagnostic tool improvement comprising a pathogen binding molecule
CN111575242A (zh) * 2020-06-04 2020-08-25 广东源心再生医学有限公司 一种用于COVID-19药物筛选的iPSC-nCoVN细胞模型及其建立和使用方法
US12156908B2 (en) 2020-07-01 2024-12-03 Regents Of The University Of Minnesota Virus like nanoparticle compositions and methods thereof
CN116710560A (zh) * 2020-08-21 2023-09-05 西湖大学 工程化ace2寡聚物及其用途
US20220226489A1 (en) 2021-01-20 2022-07-21 Singh Biotechnology, Llc Therapeutics directed against coronavirus

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1445322T2 (sl) * 1995-06-15 2012-10-30 Crucell Holland Bv Pakirni sistemi za humani rekombinantni adenovirus za gensko terapijo
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
DE60045138D1 (de) 1999-05-17 2010-12-02 Crucell Holland Bv Rekombinantes Adenovirus des Ad26-Serotyps
EP1103610A1 (de) * 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
FR2828405B1 (fr) 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
ATE453708T1 (de) 2002-11-08 2010-01-15 Crucell Holland Bv Impfstoff gegen west nile virus
EP1633775A2 (de) 2003-06-13 2006-03-15 Crucell Holland B.V. Antigene peptide des sars-coronavirus und anwendungen davon
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
WO2005012338A1 (en) 2003-07-21 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
US7396914B2 (en) * 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
WO2005032487A2 (en) * 2003-10-06 2005-04-14 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the sars coronavirus
ATE463559T1 (de) 2005-07-22 2010-04-15 Crucell Holland Bv Zelllinie zur produktion von coronaviren

Also Published As

Publication number Publication date
EP1907536A1 (de) 2008-04-09
KR20080033270A (ko) 2008-04-16
EP1907536B1 (de) 2010-04-07
AU2006271666B2 (en) 2011-04-07
CN101228267B (zh) 2013-01-23
CA2616221A1 (en) 2007-01-25
US7888102B2 (en) 2011-02-15
CA2616221C (en) 2011-07-05
KR101274790B1 (ko) 2013-06-13
WO2007010028A1 (en) 2007-01-25
AU2006271666A1 (en) 2007-01-25
DK1907536T3 (da) 2010-07-19
US20090098530A1 (en) 2009-04-16
JP2009502128A (ja) 2009-01-29
JP5137829B2 (ja) 2013-02-06
CN101228267A (zh) 2008-07-23

Similar Documents

Publication Publication Date Title
WO2009039307A3 (en) Hydrogels and methods for producing and using the same
WO2010088633A3 (en) Novel cell lines and methods
NL1026467A1 (nl) Composiet semipermeabel membraan, alsmede productiewerkwijze daarvoor.
WO2009011546A3 (en) Method for promoting the self-renewal of adult stem cells using mesenchymal stromal cells
WO2009149956A3 (en) Fusion protein and use thereof
EP2335272A4 (de) Quantenpunkte, verfahren zur herstellung von quantenpunkten und verfahren zur verwendung von quantenpunkten
IL229348A0 (en) Methods for producing activated dendritic cells
WO2009102569A3 (en) Cell lines and methods for making and using them
WO2010033906A3 (en) Efficient induction of pluripotent stem cells using small molecule compounds
GB2451999A (en) Fuel synthesis
EP2586611A4 (de) Poröse verbundmembran, verfahren zur herstellung einer porösen verbundmembran und batterieseparator damit
WO2010128024A3 (en) Reversibly immortalized cells as well as methods relating hereto
WO2010078952A3 (de) Strukturierte gasdiffusionselektrode für elektrolysezellen
CY1107014T1 (el) Χρηση θρεπτικου μεσου κυτταροκαλλιεργειας ελευθερου ορου για την παραγωγη il-18bp σε κυτταρα θηλαστικων
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
ATE463559T1 (de) Zelllinie zur produktion von coronaviren
EP2408904A4 (de) Herstellung von umprogrammierten pluripotenten zellen
BRPI0912164A2 (pt) processo para a degradação de lignina.
ATE532814T1 (de) Neue ammonium-polyurethan- und/oder polycarbonat- verbindungen
DE602007006258D1 (de) Ionenaustausch-Membranelektrolyseur
DE602005024180D1 (de) Erzeugungssystem für brennstoffzellen des polymer-elektrolyttyps
SG170081A1 (en) Method of patterning and product(s) obtained therefrom
FR2910230B3 (fr) Methodes de biofertilisations pour ameliorer la stabilite des rendements de grandes cultures agronomiques.
PL2296487T3 (pl) Sposób wytwarzania hydrolizatu białka pszenicy
PL2300606T3 (pl) Sposób wytwarzania hydrolizatu kazeiny

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1907536

Country of ref document: EP